Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
NCT Number: NCT03525106
This trial studies a positive psychology intervention designed to improve quality of life in stem cell transplant survivors and their caregivers. Positive psychology (PP) uses systematic exercises (e.g., gratitude letters, acts of kindness) to potentially boost levels of optimism, resilience, and life enjoyment. PP interventions are often enjoyable, easy to understand, and can be delivered via telephone. PP intervention may improve the quality of life of participants who have undergone a stem cell transplant or their caregivers.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Seattle, Washington, 98109, United States
PRIMARY OBJECTIVES:
I. Pilot a positive psychology intervention delivered to hematopoietic cell transplantation (HCT) survivors and interested caregivers over an 8 week period.
II. Determine the proportion of patients who enroll and the immediate benefit to participants, as measured by pre- and post-exercise measures of happiness and optimism.
III. Pilot outcome data collection mechanisms in preparation for a randomized clinical trial.
OUTLINE:
Participants and caregivers receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
After completion of study, participants are followed up at 6 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Receive positive psychology manual
Other names: Pamphlet
Complete positive psychology exercises
Ancillary studies
Other names: Quality of Life Assessment
Ancillary studies
Participate in phone sessions
Time frame: Up to 8 weeks
The analysis of the study will mainly be descriptive. The proportion of participants who consent to enroll in the study will be computed based on the number approached through each method. Reasons for non-participation will be summarized. A larger randomized trial will be considered feasible if the enrollment rate for patients approached in person or over the phone is > 50% (excluding the active opt-out rate) and the overall completeness of follow-up data collection is > 70%, excluding patients who have died or are hospitalized/ill at the assessment point.
Since the number of caregivers who will participate is unknown, caregiver analyses will also be descriptive only.
Time frame: Up to 8 weeks
Time frame: Up to 8 weeks
Completeness is defined by the proportion of instrument scores that can be calculated per given time point. The completeness of follow-up data collection will be calculated and reported as a proportion of successfully completed scales versus scales attempted to be collected or completed by patients.
Time frame: Baseline up to 8 weeks
Change in happiness for each exercise will be analyzed by change scores. A change of 2 points on a 0-10 scale, with 10 being happiest, is considered clinically meaningful.
Time frame: Baseline up to 8 weeks
Change in optimism for each exercise will be analyzed by change scores. A change of 2 points on a 0-10 scale, with 10 being most optimistic, is considered clinically meaningful.
Time frame: Baseline up to 6 months after intervention ends
This will be assessed with the patient-reported outcomes measurement information system, PROMIS-10 (Global-Mental). Higher scores are better. T scores will be used to standardize scores so that 50 represents the US general population and 10 is the standard deviation.
Time frame: Baseline up to 6 months after intervention ends
This will be assessed with the patient-reported outcomes measurement information system, PROMIS-10 (Global-Physical). Higher scores are better. T scores will be used to standardize scores so that 50 represents the US general population and 10 is the standard deviation.
Time frame: Baseline up to 6 months after intervention ends
This will be assessed with the patient-reported outcomes measurement information system, PROMIS-Fatigue. Lower scores are better. T scores will be used to standardize scores so that 50 represents the US general population and 10 is the standard deviation.
Time frame: Baseline up to 6 months after intervention ends
This will be assessed with the patient-reported outcomes measurement information system, PROMIS-Pain interference. Lower scores are better. T scores will be used to standardize scores so that 50 represents the US general population and 10 is the standard deviation.
Time frame: Baseline up to 6 months after intervention ends
This will be assessed with the Connor Davidson resilience scale. Total scores range from 0-40 with higher scores reflecting great resilience.
Time frame: Baseline up to 6 months after intervention ends
The Hospital Anxiety and Depression Scale will be used to capture depression and anxiety. Scores on the Anxiety and Depression subscales range from 0-21 with higher scores indicating more distress. Subscales will be reported separately.
Fred Hutchinson Cancer Center
Other
Feasibility of a Positive Psychology Intervention for Hematopoietic Cell Transplant Survivors to Improve Quality of Life
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03583424
Hematopoietic Cell Transplantation Recipient, Hemic and Lymphatic Diseases
Columbus, Ohio, United States
View Trial DetailsNCT01701986
Hematopoietic Cell Transplantation Recipient, Hemic and Lymphatic Diseases
Houston, Texas, United States
View Trial DetailsNCT01718743
Blood Protein Disorders, Cardiovascular Diseases
Houston, Texas, United States
View Trial DetailsNCT02860039
Hematopoietic Cell Transplantation Recipient, Infections
San Francisco, California, United States
View Trial Details